Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Wuling capsule for mild depression in early Parkinson's disease
ChiCTR2100046195Phase 4Recruiting
- Sponsor
- Xinhua Hospital
- Start
- May 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Parkinson's disease (PD) and major depressive disorder (MDD) comparing Wuling capsule with placebo (2 arms). Primary endpoint: Change in Hamilton Depression Rating Scale (HAMD-17) at 12 weeks. Started May 2021; status: recruiting.
02
Drugs
wulingshen
03
Conditions
Parkinson's disease (PD)major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2100046195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046195.